BACKGROUND: Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that hydrolyzes the endocannabinoid anandamide and related amidated signaling lipids. Genetic or pharmacological inactivation of FAAH produces analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes without showing the undesirable side effects of direct cannabinoid receptor agonists, indicating that FAAH may be a promising therapeutic target. OBJECTIVES: This review highlights advances in the development of FAAH inhibitors of different mechanistic classes and their in vivo efficacy. Also highlighted are advances in technology for the in vitro and in vivo selectivity assessment of FAAH inhibitors employing activity-based protein profiling (ABPP) and click chemistry-ABPP, respectively. Recent reports on structure-based drug design for human FAAH generated by protein engineering using interspecies active site conversion are also discussed. METHODS: The literature searches of Medline and SciFinder databases were used. CONCLUSIONS: There has been tremendous progress in our understanding in FAAH and development of FAAH inhibitors with in vivo efficacy, selectivity, and drug like pharmacokinetic properties.
BACKGROUND:Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that hydrolyzes the endocannabinoidanandamide and related amidated signaling lipids. Genetic or pharmacological inactivation of FAAH produces analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes without showing the undesirable side effects of direct cannabinoid receptor agonists, indicating that FAAH may be a promising therapeutic target. OBJECTIVES: This review highlights advances in the development of FAAH inhibitors of different mechanistic classes and their in vivo efficacy. Also highlighted are advances in technology for the in vitro and in vivo selectivity assessment of FAAH inhibitors employing activity-based protein profiling (ABPP) and click chemistry-ABPP, respectively. Recent reports on structure-based drug design for humanFAAH generated by protein engineering using interspecies active site conversion are also discussed. METHODS: The literature searches of Medline and SciFinder databases were used. CONCLUSIONS: There has been tremendous progress in our understanding in FAAH and development of FAAH inhibitors with in vivo efficacy, selectivity, and drug like pharmacokinetic properties.
Authors: Anna Minkkilä; Susanna M Saario; Heikki Käsnänen; Jukka Leppänen; Antti Poso; Tapio Nevalainen Journal: J Med Chem Date: 2008-11-27 Impact factor: 7.446
Authors: D G Deutsch; R Omeir; G Arreaza; D Salehani; G D Prestwich; Z Huang; A Howlett Journal: Biochem Pharmacol Date: 1997-02-07 Impact factor: 5.858
Authors: Benjamin F Cravatt; Alan Saghatelian; Edward G Hawkins; Angela B Clement; Michael H Bracey; Aron H Lichtman Journal: Proc Natl Acad Sci U S A Date: 2004-07-09 Impact factor: 11.205
Authors: Christophe Hardouin; Michael J Kelso; F Anthony Romero; Thomas J Rayl; Donmienne Leung; Inkyu Hwang; Benjamin F Cravatt; Dale L Boger Journal: J Med Chem Date: 2007-06-09 Impact factor: 7.446
Authors: Giulia Palermo; Davide Branduardi; Matteo Masetti; Alessio Lodola; Marco Mor; Daniele Piomelli; Andrea Cavalli; Marco De Vivo Journal: J Med Chem Date: 2011-09-08 Impact factor: 7.446
Authors: Pretal P Muldoon; Lois S Akinola; Joel E Schlosburg; Aron H Lichtman; Laura J Sim-Selley; Anu Mahadevan; Benjamin F Cravatt; M Imad Damaj Journal: Neuropharmacology Date: 2020-05-30 Impact factor: 5.250
Authors: Ashfaq Ahmad; Sara K Dempsey; Zdravka Daneva; Ningjun Li; Justin L Poklis; Pin-Lan Li; Joseph K Ritter Journal: Am J Physiol Renal Physiol Date: 2018-05-30
Authors: Katerina Otrubova; Monica Brown; Michael S McCormick; Gye W Han; Scott T O'Neal; Benjamin F Cravatt; Raymond C Stevens; Aron H Lichtman; Dale L Boger Journal: J Am Chem Soc Date: 2013-04-12 Impact factor: 15.419